The aim of the present study was to compare the efficacy, safety and glycemic variability outcomes of a combined basal–DPP4-i regime compared to a conventional basal–bolus insulin regimen in internal medicine patients with T2DM. The gene discussed is INS; the disease is type 2 diabetes mellitus.